GT Biopharma Inc.(GTBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GTBP GT Biopharma Inc.

Post-Mkt 01-21 19:30:10 EST

0.7100

-0.0153

-2.11%

盘后0.6960

-0.0140-1.97%

18:41 EST

High0.7253	Low0.6800	Vol868.65K
Open0.7253	D1 Closing0.7253	Amplitude6.25%
Mkt Cap7.55M	Tradable Cap6.58M	Total Shares10.64M
T/O606.70K	T/O Rate9.38%	Tradable Shares9.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GTBP","market":"US","secType":"STK","nameCN":"GT Biopharma Inc.","latestPrice":0.71,"timestamp":1769029200000,"preClose":0.7253,"halted":0,"volume":868650,"hourTrading":{"tag":"盘后","latestPrice":0.696,"preClose":0.71,"latestTime":"18:41 EST","volume":19213,"amount":13376.36227182,"timestamp":1769038894552,"change":-0.014,"changeRate":-0.019718,"amplitude":0.057042},"delay":0,"changeRate":-0.021094719426444204,"floatShares":9262500,"shares":10636135,"eps":-3.3776,"marketStatus":"Post-Mkt","change":-0.0153,"latestTime":"01-21 19:30:10 EST","open":0.7253,"high":0.7253,"low":0.68,"amount":606696.691995,"amplitude":0.062457,"askPrice":0.73,"askSize":261,"bidPrice":0.652,"bidSize":1533,"shortable":3,"etf":0,"ttmEps":-3.3776,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1769043600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.7253,"preHourTrading":{"tag":"盘前","latestPrice":0.715,"preClose":0.7253,"latestTime":"09:24 EST","volume":30556,"amount":21867.12150704,"timestamp":1769005480092,"change":-0.0103,"changeRate":-0.014201,"amplitude":0.020681},"postHourTrading":{"tag":"盘后","latestPrice":0.696,"preClose":0.71,"latestTime":"18:41 EST","volume":19213,"amount":13376.36227182,"timestamp":1769038894552,"change":-0.014,"changeRate":-0.019718,"amplitude":0.057042},"volumeRatio":0.313248,"impliedVol":2.3584,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/GTBP/wiki","defaultTab":"wiki","newsList":[{"id":"2603880029","title":"GT Biopharma submits IND application to U.S. FDA for GTB-5550 TriKE","url":"https://stock-news.laohu8.com/highlight/detail?id=2603880029","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603880029?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:36","pubTimestamp":1768484182,"startTime":"0","endTime":"0","summary":"GT Biopharma (GTBP) announced the submission of an investigational new drug, IND, application to the U.S. Food and Drug Administration, FDA, in Dec...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gt-biopharma-submits-ind-application-to-u-s-fda-for-gtb-5550-trike-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gt-biopharma-submits-ind-application-to-u-s-fda-for-gtb-5550-trike-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GTBP","BK4585","IND","GT","BK4139","BK4119","BK4588"],"gpt_icon":0},{"id":"2603998897","title":"GT Biopharma Announces Ind Submission for Gtb-5550 Trike®, a B7-H3-Targeted Natural Killer (Nk) Cell Engager for B7-H3 Expressing Solid Tumor Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2603998897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603998897?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:30","pubTimestamp":1768483858,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GTBP"],"gpt_icon":0},{"id":"2603071600","title":"EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2603071600","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603071600?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:01","pubTimestamp":1768482060,"startTime":"0","endTime":"0","summary":"GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/15/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/15/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/01/49931692/exclusive-gt-biopharma-plans-2026-trial-for-new-cancer-treatment","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/01/49931692/exclusive-gt-biopharma-plans-2026-trial-for-new-cancer-treatment","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1721428933.USD","BK4548","BK4585","PFS","BK4139","GT","BK4533","BK4121","LU1093756325.SGD","MTD","LU2413666699.HKD","GTBP","IE00BFXG0V08.USD","BK4567","BK4119","BK4195","LU2413666426.HKD","IND","BK4211","BK4588","LU0347712357.USD","OS","IE00BYQQ9H92.USD","LU2211817866.USD","LU1093756168.USD","IE00B5TLWC47.USD","BK4097"],"gpt_icon":0},{"id":"2593479961","title":"GT Biopharma Advances Phase 1 Trial of GTB-3650 for Relapsed Blood Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2593479961","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593479961?lang=en_us&edition=fundamental","pubTime":"2025-12-24 19:00","pubTimestamp":1766574024,"startTime":"0","endTime":"0","summary":"GT Biopharma Inc. has announced continued progress in its Phase 1 clinical trial evaluating GTB-3650 in cancer patients. The trial has advanced to Cohort 4 at a dose level of 10 g/kg/day. Six patients in Cohorts 1 through 3 have completed treatment, establishing the therapy's safety profile across escalating doses with no dose-limiting toxicities observed. The company indicated that the current dose level may be within the range where clinical efficacy is more likely, supported by encouraging immunological biomarker trends. The first-in-human Phase 1 protocol plans to enroll approximately 14 patients across seven dose-escalation cohorts, potentially reaching a maximum dose of 100 g/kg/day. GT Biopharma anticipates providing its next comprehensive trial update in the first quarter of 2026. In addition, GT Biopharma is preparing to initiate human trials for GTB-5550, a therapy targeting B7H3, a protein found in several solid tumors. Regulatory submission for the GTB-5550 trial is expecte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDLbrfJmd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","LU2095319765.USD","BK4139","GTBP","LU2210150020.SGD","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","SG9999014005.SGD","BK4588","LU2210149790.SGD","LU0314104364.USD","BK4585","SG9999014021.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2586829837","title":"GT Biopharma Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2586829837","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586829837?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:31","pubTimestamp":1764192717,"startTime":"0","endTime":"0","summary":"GT Biopharma Inc. has received a notice from the Nasdaq Stock Market indicating that its common stock has closed below the $1 minimum bid price requirement for 30 consecutive business days, putting the company out of compliance with Nasdaq Listing Rule 5550. The company has been granted a 180-day period until May 19, 2026, to regain compliance by achieving a closing bid price of at least $1 per share for ten consecutive business days. If compliance is not regained within this period, GT Biopharma may be eligible for an additional 180-day extension, subject to meeting other listing requirements. Failure to comply could result in the delisting of the company's stock from the Nasdaq Capital Market.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL6gjXZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTBP","BK4139"],"gpt_icon":0},{"id":"2584620791","title":"GT Biopharma (GTBP) Gets a Buy from Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2584620791","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584620791?lang=en_us&edition=fundamental","pubTime":"2025-11-18 00:55","pubTimestamp":1763398538,"startTime":"0","endTime":"0","summary":"In a report released on November 14, Jonathan Aschoff from Roth MKM maintained a Buy rating on GT Biopharma, with a price target of $8.00. Aschoff ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/gt-biopharma-gtbp-gets-a-buy-from-roth-mkm-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/gt-biopharma-gtbp-gets-a-buy-from-roth-mkm-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GT","GTBP","BK4585","BK4139","BK4119","BK4588"],"gpt_icon":0},{"id":"2583501068","title":"GT Biopharma Inc: Holds $2.6M Cash and Cash Equivalents as of Sept 30, Funding Operations Through Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583501068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583501068?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:00","pubTimestamp":1763128802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUA3WFMPP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GTBP"],"gpt_icon":0},{"id":"2583059501","title":"GT Biopharma Inc: Anticipates Submission of Ind Application for Gtb-5550 in Late December 2025 or in January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583059501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583059501?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:00","pubTimestamp":1763128802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUA3WFMPP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GTBP"],"gpt_icon":0},{"id":"2578540540","title":"GT Biopharma files to sell 14.59M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2578540540","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578540540?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:20","pubTimestamp":1761337216,"startTime":"0","endTime":"0","summary":"16:17 EDT GT Biopharma (GTBP) files to sell 14.59M shares of common stock for holders Published first on TheFly – the ultimate source for real-time...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gt-biopharma-files-to-sell-14-59m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gt-biopharma-files-to-sell-14-59m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","GT","BK4588","GTBP","BK4119"],"gpt_icon":0},{"id":"2577302020","title":"BRIEF-GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2577302020","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577302020?lang=en_us&edition=fundamental","pubTime":"2025-10-23 21:07","pubTimestamp":1761224842,"startTime":"0","endTime":"0","summary":"BRIEF-GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic MalignanciesOct 23 (Reuters) - GT Biopharma Inc GTBP.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA1NKLJW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTBP","BK4139"],"gpt_icon":0},{"id":"2577530243","title":"GT Biopharma Provides Enrollment Update on Gtb-3650 Phase 1 Trial in Patients With Relapsed or Refractory (R/R) Cd33 Expressing Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2577530243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577530243?lang=en_us&edition=fundamental","pubTime":"2025-10-23 21:00","pubTimestamp":1761224405,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA1NKLJW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GTBP"],"gpt_icon":0},{"id":"2577234302","title":"GT Biopharma Inc - Screening Patients for Cohort 4, Dosing to Start Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2577234302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577234302?lang=en_us&edition=fundamental","pubTime":"2025-10-23 21:00","pubTimestamp":1761224405,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA1NKLJW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GTBP","BK4139"],"gpt_icon":0},{"id":"2577230223","title":"GT Biopharma Inc - Advances to Cohort 4 With 10 Ug/Kg/Day Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2577230223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577230223?lang=en_us&edition=fundamental","pubTime":"2025-10-23 21:00","pubTimestamp":1761224405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA1NKLJW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GTBP","BK4139"],"gpt_icon":0},{"id":"2577022393","title":"GT Biopharma Inc - Next Update Expected in Q1 2026 With Dose Escalation","url":"https://stock-news.laohu8.com/highlight/detail?id=2577022393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577022393?lang=en_us&edition=fundamental","pubTime":"2025-10-23 21:00","pubTimestamp":1761224405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA1NKLJW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GTBP"],"gpt_icon":0},{"id":"2573925095","title":"GT Biopharma Provides Enrollment Update on Gtb-3650 Phase 1 Trial in Patients With Relapsed or Refractory (R/R) Cd33 Expressing Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2573925095","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573925095?lang=en_us&edition=fundamental","pubTime":"2025-10-08 21:00","pubTimestamp":1759928402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUABJVDMX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GTBP","BK4139"],"gpt_icon":0},{"id":"2573263229","title":"GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2573263229","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573263229?lang=en_us&edition=fundamental","pubTime":"2025-10-08 21:00","pubTimestamp":1759928400,"startTime":"0","endTime":"0","summary":"The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/08/3163394/0/en/GT-Biopharma-Provides-Enrollment-Update-on-GTB-3650-Phase-1-Trial-in-Patients-with-Relapsed-or-Refractory-r-r-CD33-Expressing-Hematologic-Malignancies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTBP","BK4119","BK4139","GT","BK4588","BK4585"],"gpt_icon":0},{"id":"2573677773","title":"GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2573677773","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573677773?lang=en_us&edition=fundamental","pubTime":"2025-10-06 21:00","pubTimestamp":1759755600,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, CALIFORNIA, Oct.  06, 2025  (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/06/3161768/0/en/GT-Biopharma-to-Participate-in-the-Centurion-One-Capital-3rd-Annual-Bahamas-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4211","GT","GTBP","SMMF","BK4139","BK4119"],"gpt_icon":0},{"id":"2570832998","title":"GT Biopharma Preferred Shareholders Waive Redemption Rights on Series L Convertible Preferred Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2570832998","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570832998?lang=en_us&edition=fundamental","pubTime":"2025-09-27 04:20","pubTimestamp":1758918036,"startTime":"0","endTime":"0","summary":"GT Biopharma Inc. has announced that all holders of its Series L 10% Convertible Preferred Stock have agreed to waive their rights to redemption as provided in the stock's certificate of designation. The waivers, received from holders on several dates in September 2025, mean that Series L Preferred Stockholders will no longer be able to require the company to redeem their shares under the previously established terms. This modification impacts the rights of security holders and alters the conditions under which the preferred shares may be repaid or converted.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL707dpv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTBP","BK4139"],"gpt_icon":0},{"id":"2569974994","title":"GT Biopharma Inc. Announces Waiver of Redemption Rights for Series L Preferred Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2569974994","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569974994?lang=en_us&edition=fundamental","pubTime":"2025-09-24 05:31","pubTimestamp":1758663087,"startTime":"0","endTime":"0","summary":"GT Biopharma Inc. has announced a significant development regarding its Series L 10% Convertible Preferred Stock. The company reported that on September 17, 18, and 23, 2025, certain holders of this preferred stock provided a waiver to the Certificate of Designation, agreeing to forgo their rights to redemption as outlined in Section 10 of the document. This waiver represents a material modification to the rights of these security holders, allowing GT Biopharma greater flexibility in managing its financial obligations related to the Series L Preferred Stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL90f46z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTBP","BK4139"],"gpt_icon":0},{"id":"2563071046","title":"GT Biopharma Inc. Renews CEO Michael Breen's Contract for Additional Two Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2563071046","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563071046?lang=en_us&edition=fundamental","pubTime":"2025-08-30 04:16","pubTimestamp":1756498577,"startTime":"0","endTime":"0","summary":"GT Biopharma Inc. announced a management change with the renewal of Michael Breen's position as Chief Executive Officer. The company's Board of Directors has extended Mr. Breen's term for an additional two years, starting from April 29, 2025. His employment will continue to automatically renew for subsequent two-year periods unless either party provides a ninety-day written notice of non-renewal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL18h3rH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTBP","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.gtbiopharma.com","stockEarnings":[{"period":"1week","weight":0.0582},{"period":"1month","weight":-0.0417},{"period":"3month","weight":0.0814},{"period":"6month","weight":-0.6611},{"period":"1year","weight":-0.6965},{"period":"ytd","weight":-0.0763}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.034146},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.141386},{"month":3,"riseRate":0.428571,"avgChangeRate":0.037703},{"month":4,"riseRate":0.428571,"avgChangeRate":0.030127},{"month":5,"riseRate":0.625,"avgChangeRate":0.082319},{"month":6,"riseRate":0.5,"avgChangeRate":0.017541},{"month":7,"riseRate":0.25,"avgChangeRate":-0.059541},{"month":8,"riseRate":0.125,"avgChangeRate":-0.133669},{"month":9,"riseRate":0.125,"avgChangeRate":-0.164268},{"month":10,"riseRate":0.75,"avgChangeRate":0.054196},{"month":11,"riseRate":0.125,"avgChangeRate":-0.132411},{"month":12,"riseRate":0.375,"avgChangeRate":0.036951}],"exchange":"NASDAQ","name":"GT Biopharma Inc.","nameEN":"GT Biopharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GT Biopharma Inc.(GTBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GT Biopharma Inc.(GTBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GT Biopharma Inc.,GTBP,GT Biopharma Inc.股票,GT Biopharma Inc.股票老虎,GT Biopharma Inc.股票老虎国际,GT Biopharma Inc.行情,GT Biopharma Inc.股票行情,GT Biopharma Inc.股价,GT Biopharma Inc.股市,GT Biopharma Inc.股票价格,GT Biopharma Inc.股票交易,GT Biopharma Inc.股票购买,GT Biopharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GT Biopharma Inc.(GTBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GT Biopharma Inc.(GTBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}